vs
Side-by-side financial comparison of Ovid Therapeutics Inc. (OVID) and Pineapple Financial Inc. (PAPL). Click either name above to swap in a different company.
Ovid Therapeutics Inc. is the larger business by last-quarter revenue ($718.0K vs $707.3K, roughly 1.0× Pineapple Financial Inc.). On growth, Ovid Therapeutics Inc. posted the faster year-over-year revenue change (844.7% vs -4.8%). Over the past eight quarters, Ovid Therapeutics Inc.'s revenue compounded faster (120.3% CAGR vs -2.0%).
OVID vs PAPL — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $718.0K | $707.3K |
| Net Profit | — | $-19.5M |
| Gross Margin | — | 48.9% |
| Operating Margin | — | -2518.8% |
| Net Margin | — | -2756.2% |
| Revenue YoY | 844.7% | -4.8% |
| Net Profit YoY | 204.4% | -3174.1% |
| EPS (diluted) | — | $-1.21 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $707.3K | ||
| Q4 25 | $718.0K | $721.7K | ||
| Q3 25 | $132.0K | $730.5K | ||
| Q2 25 | $6.3M | $746.9K | ||
| Q1 25 | $130.0K | $743.3K | ||
| Q4 24 | $76.0K | $766.1K | ||
| Q3 24 | $173.0K | $598.3K | ||
| Q2 24 | $169.0K | $736.4K |
| Q1 26 | — | $-19.5M | ||
| Q4 25 | — | $-6.4M | ||
| Q3 25 | $-12.2M | $-1.8M | ||
| Q2 25 | $-4.7M | $-557.7K | ||
| Q1 25 | $-10.2M | $-595.4K | ||
| Q4 24 | — | $-656.9K | ||
| Q3 24 | $-14.0M | $-1.7M | ||
| Q2 24 | $8.5M | $-848.6K |
| Q1 26 | — | 48.9% | ||
| Q4 25 | — | 49.6% | ||
| Q3 25 | — | 27.8% | ||
| Q2 25 | — | 67.6% | ||
| Q1 25 | — | 43.4% | ||
| Q4 24 | — | 45.9% | ||
| Q3 24 | — | 43.2% | ||
| Q2 24 | — | 44.2% |
| Q1 26 | — | -2518.8% | ||
| Q4 25 | — | -909.1% | ||
| Q3 25 | -9487.1% | -131.3% | ||
| Q2 25 | -80.9% | -93.3% | ||
| Q1 25 | -9653.8% | -80.6% | ||
| Q4 24 | — | -90.5% | ||
| Q3 24 | -7645.1% | -232.8% | ||
| Q2 24 | -12140.2% | -121.7% |
| Q1 26 | — | -2756.2% | ||
| Q4 25 | — | -891.6% | ||
| Q3 25 | -9210.6% | -250.3% | ||
| Q2 25 | -74.7% | -74.7% | ||
| Q1 25 | -7873.1% | -80.1% | ||
| Q4 24 | — | -85.7% | ||
| Q3 24 | -8096.0% | -283.9% | ||
| Q2 24 | 5042.0% | -115.2% |
| Q1 26 | — | $-1.21 | ||
| Q4 25 | — | $-4.79 | ||
| Q3 25 | — | $-0.93 | ||
| Q2 25 | — | $-0.05 | ||
| Q1 25 | — | $-1.73 | ||
| Q4 24 | — | $-2.60 | ||
| Q3 24 | $-0.20 | $-11.10 | ||
| Q2 24 | $0.12 | $-0.12 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $13.2M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $130.7M | $27.1M |
| Total Assets | $150.9M | $48.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $13.2M | — | ||
| Q3 25 | $20.6M | — | ||
| Q2 25 | $28.4M | — | ||
| Q1 25 | $21.1M | — | ||
| Q4 24 | $26.3M | — | ||
| Q3 24 | $15.0M | — | ||
| Q2 24 | $29.7M | — |
| Q1 26 | — | $27.1M | ||
| Q4 25 | $130.7M | $-5.5M | ||
| Q3 25 | $44.7M | $906.7K | ||
| Q2 25 | $55.8M | $842.6K | ||
| Q1 25 | $59.3M | $739.7K | ||
| Q4 24 | $68.2M | $1.3M | ||
| Q3 24 | $76.3M | $1.3M | ||
| Q2 24 | $88.9M | $2.0M |
| Q1 26 | — | $48.9M | ||
| Q4 25 | $150.9M | $10.6M | ||
| Q3 25 | $63.8M | $5.4M | ||
| Q2 25 | $77.4M | $4.7M | ||
| Q1 25 | $81.7M | $4.0M | ||
| Q4 24 | $92.2M | $4.1M | ||
| Q3 24 | $102.7M | $4.1M | ||
| Q2 24 | $118.1M | $4.3M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-38.3M | $-3.3M |
| Free Cash FlowOCF − Capex | — | $-3.3M |
| FCF MarginFCF / Revenue | — | -462.7% |
| Capex IntensityCapex / Revenue | 0.0% | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $-3.3M | ||
| Q4 25 | $-38.3M | $-489.7K | ||
| Q3 25 | $-12.9M | $-507.6K | ||
| Q2 25 | $-4.8M | $397.0K | ||
| Q1 25 | $-10.3M | $-172.6K | ||
| Q4 24 | $-56.0M | $-663.6K | ||
| Q3 24 | $-15.0M | $-264.7K | ||
| Q2 24 | $-14.3M | $123.0K |
| Q1 26 | — | $-3.3M | ||
| Q4 25 | — | $-491.7K | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $-56.0M | — | ||
| Q3 24 | $-15.0M | $-264.7K | ||
| Q2 24 | $-14.3M | $122.7K |
| Q1 26 | — | -462.7% | ||
| Q4 25 | — | -68.1% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | -73719.7% | — | ||
| Q3 24 | -8676.9% | -44.2% | ||
| Q2 24 | -8455.0% | 16.7% |
| Q1 26 | — | 0.0% | ||
| Q4 25 | 0.0% | 0.3% | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 0.0% | — | ||
| Q4 24 | 93.4% | — | ||
| Q3 24 | 2.3% | 0.0% | ||
| Q2 24 | 20.1% | 0.0% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -1.67× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
